Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

560.75 -3.15 (-0.56%)
Official Closing Price Updated: 4:15 PM EDT, Sep 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder
The U.S. 
Via Benzinga
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials
Via Stocktwits
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare... 
Via StockStory
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
What Does the Market Think About Regeneron Pharmaceuticals?
 
Via Benzinga
Why Regeneron (REGN) Stock Is Down Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its... 
Via StockStory
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday?
Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records. 
Via Benzinga
Discover which S&P500 stocks are making waves on Tuesday.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
Tuesday's session: gap up and gap down stock in the S&P500 index
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends. 
Via Chartmill
1 S&P 500 Stock on Our Buy List and 2 We Turn Down
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025. 
Via Benzinga
REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals
Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors. 
Via Chartmill
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma. 
Via Investor's Business Daily
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder
Regeneron's Phase 3 trial of garetosmab showed a 90%+ reduction in new bone lesions for FOP, with no deaths and good safety over 56 weeks. 
Via Benzinga
Topics Death
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
Libtayo plus chemotherapy showed superior survival and response rates over five years in advanced NSCLC patients without EGFR, ALK, or ROS1 mutations. 
Via Benzinga
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,... 
Via MarketMinute
Topics Economy Government World Trade
Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a... 
Via MarketMinute
Topics Economy Supply Chain World Trade
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development. 
Via Benzinga
2 Beaten-Down Stocks to Buy on the Dip
The market may be overlooking these companies' long-term potential. 
Via The Motley Fool
Topics Government World Trade
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades'
Cisco reported fourth-quarter revenue of $14.67 billion, and there was a bout of profit taking, Cerity Partners' Jim Lebenthal says. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.